Global Expertise, Local Impact
The Role of CRMY’s Scientific Advisory Committee in Advancing Cancer Research
Cancer Research Malaysia (CRMY) recently hosted a review of its research programmes by the esteemed members of its Scientific Advisory Committee (SAC). Comprising international experts, the SAC plays a pivotal role in guiding CRMY’s research direction, evaluating its quality and impact and advising the Board of Trustees and management. This rigorous process serves as an international benchmark of excellence, reaffirming CRMY’s position as a leading force in cancer research, particularly for the Asian population.
The SAC’s input is invaluable, providing assurance to CRMY and its donors that the organisation is on the right path toward achieving transformative outcomes in cancer prevention, diagnosis and treatment. By identifying research priorities, recruiting top talent, and facilitating knowledge exchange, the SAC ensures CRMY’s work addresses the unique challenges faced by Asian communities while contributing to global cancer research advancements.
This year, during their visit to CRMY, SAC members conducted an in-depth evaluation of ongoing research programmes. Their recommendations not only enhance the quality of CRMY’s projects but also reinforce its commitment to peer-review excellence. By shaping strategies and setting ambitious goals, the SAC strengthens CRMY’s ability to deliver groundbreaking solutions that benefit patients across Malaysia and Asia.
To understand the SAC’s impact, we spoke with several of its members, each bringing invaluable expertise and perspectives to our work:
Professor Adrian Harris
Cancer Research UK Professor of Medical Oncology, University of Oxford
What stands out to you about the programmes at Cancer Research Malaysia?
“CRMY’s work is defined by quality and international impact. Their focus on underprivileged communities and innovative care models is exceptional. To tackle disparities, you must understand the disease itself, CRMY does just that.”
Why is it important to focus on Asian cancers?
“Global funding rarely prioritises research on Asian cancers. CRMY’s work fills a critical gap, ensuring that Malaysians and Asians more broadly benefit from tailored solutions. Tools like telemedicine for oral cancer detection have the potential to revolutionise care not just in Malaysia but worldwide.”
Professor Aik Choon Tan
Senior Director of Data Science, Huntsman Cancer Institute, University of Utah
How does CRMY leverage data science to accelerate cancer research?
“CRMY’s bioinformatics efforts are exceptional, particularly the Asian breast cancer cohort that spans Malaysia’s diverse ethnic groups. They use innovative AI and machine learning to identify unique patterns beneficial to Malaysian breast cancer patients.”
What impact do CRMY’s oral cancer programmes have on cancer research?
“I’ve observed CRMY since 2008, and its growth has been remarkable. The oral cancer programme is especially unique, creating clinical models and datasets specific to Asian populations.”
Professor Jon Emery
Herman Professor of Primary Care Cancer Research, University of Melbourne
In your experience, what makes CRMY’s focus on cancer prevention in Asian populations so impactful?
“By tailoring cancer prevention tools to the genetic makeup of the Malaysian population, CRMY is leading globally in precision medicine for Asians. Their breast cancer research, particularly the polygenic risk score, is internationally groundbreaking.”
Which CRMY programmes stand out to you the most?
“CRMY excels across the spectrum, from basic to translational science to implementation. The Community Outreach, Digital Health, and population health programmes are particularly impressive. Initiatives like the oral cancer screening and patient navigation programme have even scaled nationally.”
Mr Wong Lup Hang
Patient Advocate
Where do you see CRMY in 10 years?
“We’ve set clear goals for the next decade, advancing diagnostic methods, enhancing prevention strategies and developing impactful treatments. Staying focused on these objectives will enable us to meet these significant challenges.”
Why should people invest in CRMY’s work?
“Without CRMY, Asians would be forgotten in the global fight against cancer. Donations are essential to empower this critical work. Every contribution ensures CRMY can continue to address the unique challenges faced by our communities.”
CRMY’s success relies on the strong collaboration between the SAC, management, and Board of Trustees. This partnership not only upholds the organisation’s reputation for excellence but also attracts top talent, ensuring impactful results for patients.
However, CRMY cannot achieve this alone. The generous support of donors is crucial in turning research into actionable solutions. Together, we can create a future where cancer is no longer a fearsome adversary but a manageable condition.
As CRMY continues to grow and innovate, the SAC review reaffirms that the organisation is on the right path, pioneering research, transforming lives, and solidifying its position as a global leader in cancer research for Asians.
With the guidance of the Scientific Advisory Committee and the unwavering support of our donors, CRMY is shaping a future free from the fear of cancer.